Hutchmed (China) Limited
Biopharmaceutical firm developing targeted therapies for cancer and immune diseases.
HCM | HKEX
Overview
Corporate Details
- ISIN(s):
- KYG4672N1198 (+1 more)
- LEI:
- 2138006X34YDQ6OBYE79
- Country:
- Hong Kong
- Address:
- LEVEL 18, THE METROPOLIS TOWER, KOWLOON
- Website:
- https://www.hutch-med.com/
- Sector:
- Manufacturing
Description
Hutchmed is a commercial-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapeutics and immunotherapies. The company operates a fully integrated platform, advancing a pipeline of novel drug candidates for the treatment of cancer and immunological diseases. Its research and development strategy focuses on creating highly selective and potent therapies engineered to improve drug exposure and reduce off-target toxicities. Hutchmed has multiple internally discovered medicines approved and marketed for various oncology and immunology indications, supported by a global commercialization infrastructure.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-03-11 08:00 |
2018 FY Results and Key Clinical Programs Update
|
English | 1.4 MB | ||
| 2019-02-12 08:00 |
Savolitinib PRCC Data to be presented at ASCO GU
|
English | 27.5 KB | ||
| 2019-02-08 08:00 |
Chi-Med to Announce 2018 Final Results
|
English | 20.1 KB | ||
| 2019-01-07 08:00 |
Chi-Med Presents at JPM Healthcare Conference
|
English | 21.6 KB | ||
| 2018-12-31 08:00 |
Blocklisting Six Monthly Return
|
English | 33.6 KB | ||
| 2018-12-31 08:00 |
Total Voting Rights
|
English | 19.4 KB | ||
| 2018-12-24 13:41 |
Second Price Monitoring Extn
|
English | 8.3 KB | ||
| 2018-12-24 13:36 |
Price Monitoring Extension
|
English | 8.3 KB | ||
| 2018-12-20 08:13 |
Chi-Med announce Savolitinib program update
|
English | 41.2 KB | ||
| 2018-12-20 08:00 |
Amendment to Lilly Agreement on Fruquintinib
|
English | 54.2 KB | ||
| 2018-12-14 08:21 |
TR-1: Form for notification of major holdings
|
English | 55.0 KB | ||
| 2018-11-30 08:00 |
Total Voting Rights
|
English | 19.4 KB | ||
| 2018-11-29 09:00 |
Chi-Med Enters into Multiple Collaborations
|
English | 26.9 KB | ||
| 2018-11-26 08:00 |
First Commercial Launch of Fruquintinib Capsules
|
English | 33.5 KB | ||
| 2018-11-16 08:00 |
Phase III FALUCA Trial Results for Fruquintinib
|
English | 32.2 KB |
Automate Your Workflow. Get a real-time feed of all Hutchmed (China) Limited filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Hutchmed (China) Limited
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Hutchmed (China) Limited via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
